Phase I/II clinical trial - VADS

COPAN-ORL 06
VADS
Essai clinique fermé
Public cible
Adulte
Phase Ib/II trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) harboring a PI3KCA mutation/amplification and/or a PTEN loss. COPAN - ORL06
Description de l'essai

This is a trial evaluating the efficacy of the combination of copanlisib, a PI3K inhibitor, with cetuximab in patients with recurrent head and neck cancer whose tumor harbour a PI3KCA mutation/amplification or a PTEN loss. PI3KCA and PTEN analyses are performed at the Institut Curie from archival tissue.